Human Interferon—β Therapy for Cerebral Primitive Neuroectodermal Tumors —Two Case Reports—

Satoshi TANAKA; Masaaki OKADA; Mineko MURAKAMI; Makoto HIRAKAWA; Shinya MANAKA; Tadashi NAGASHIMA

doi:10.2176/nmc.35.82

Human Interferon—β Therapy for Cerebral Primitive Neuroectodermal Tumors

—Two Case Reports—

Satoshi TANAKA, Masaaki OKADA, Mineko MURAKAMI, Makoto HIRAKAWA, Shinya MANAKA, Tadashi NAGASHIMA

Author information

Satoshi TANAKA
Department of Neurosurgery, Ichihara Hospital, Teikyo University School of Medicine

Masaaki OKADA
Department of Neurosurgery, Ichihara Hospital, Teikyo University School of Medicine

Mineko MURAKAMI
Department of Neurosurgery, Ichihara Hospital, Teikyo University School of Medicine

Makoto HIRAKAWA
Department of Neurosurgery, Ichihara Hospital, Teikyo University School of Medicine

Shinya MANAKA
Department of Neurosurgery, Ichihara Hospital, Teikyo University School of Medicine

Tadashi NAGASHIMA
Department of Neurosurgery, Ichihara Hospital, Teikyo University School of Medicine

Corresponding author

Keywords: brain tumor, children, human interferon-β, primitive neuroectodermal tumor

JOURNAL FREE ACCESS

1995 Volume 35 Issue 2 Pages 82-86

DOI https://doi.org/10.2176/nmc.35.82

Details

Published: 1995 Received: April 28, 1994 Available on J-STAGE: March 30, 2006 Accepted: August 05, 1994 Advance online publication: - Revised: -

Download PDF (539K)
Download citation RIS
(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX
(compatible with BibDesk, LaTeX)

Text

How to download citation
Contact us

Abstract

A 5-year-old girl and a 2-year-old boy presented with recurrent cerebral primitive neuroectodermal tumor (PNET) and were treated with intravenous administration of human fibroblast interferon (HuIFN-β) which was continued as outpatient maintenance therapy. Both patients showed a partial response and were still alive 14 months and 2 years after diagnosis. Our results suggest that HuIFN-β is an effective therapy for PNET, and can be used as long-term maintenance therapy without serious side effects.

Corresponding author

Register with J-STAGE for free!